Clinical trial
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or…
NCT00078975 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00078975 |
|---|---|
| Title | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer |
| Official title | A Phase II Study of Triapine in Combination With Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, triapine |
| Enrollment | 26 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Jan 7, 2009 |
| First posted | Mar 9, 2004 |
| Last update posted | Sep 14, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: